Latest Media Releases (Page 9) | Finance News Network

Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep - New Biomarker Data from TACTI-002 trial in 1st line NSCLC (ASX:IMM)

Statistically significant increases of Th1 biomarkers (IFN-gamma, CXCL-10), circulating immune cells (lymphocytes), and RNA levels of immune activating genes were observed...read more

Austco Healthcare wins $3.8m Order (ASX:AHC)

Austco Healthcare wins AUD $3.8 million contract to refresh nurse call system for Jurong Health Campus in Singapore Austco Healthcare Limited (ASX: AHC) ("Austco") is proud to anno...read more

Chimeric Therapeutics - 1st patient dosed in Phase 1b recurrent glioblastoma trial (ASX:CHM)

1st patient dosed in the Phase 1B with CHM 1101 in brain cancer clinical trial The Phase 1B clinical trial builds off the recent positive Phase 1A clinical data Phase 1B ...read more

Austco Healthcare - CEO's Address to Shareholders (ASX:AHC)

To view the presentation, download the attached PDF.

Radiopharm Theranostics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:RAD)

Highlights: FDA IND for Trivehexin (RAD 301) diagnostic Phase 1 pancreatic clinical trial RAD 301 additional data on 33 patients presented at 2023 European Association of Nuclear ...read more

Chimeric Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:CHM)

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 30...read more

Chimeric Therapeutics - FDA clearance of IND for CHM 2101 (ASX:CHM)

FDA IND Clearance for CHM 2101, a novel 3rd generation CDH17 CAR T cell therapy Anticipated to be the first CDH17 CAR T cell therapy to enter the clinic Phase 1A clinical...read more

Immutep Quarterly Activities Report and Appendix 4C (ASX:IMM)

Excellent survival benefit in 1st line non-small cell lung cancer (1L NSCLC) in TACTI-002 trial: median Overall Survival of 35.5 months (TPS ≥1% patients) providing additional 12-18 mon...read more

Radiopharm Theranostics - Entitlement Offer to raise approximately $10 million (ASX:RAD)

Key Points -- Non-renounceable entitlement offer to raise up to approximately $10 million (before direct offer costs). -- Offer price of $0.07 per new share, a 30.0% discount to the closing pric...read more

INOVIQ - Appendix 4C and Quarterly Activities Report - September 2023 (ASX:IIQ)

-- INOVIQ and Promega sign a global joint marketing agreement for INOVIQ’s EXO-NET® exosome capture technology and Promega Nucleic Acid purification systems -- INOVIQ and ResearchDx sign ...read more

Immutep receives Australian R&D Tax Incentive (ASX:IMM)

SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,134,882 cash rebate from the Aust...read more

Immutep - Results of Meeting (ASX:IMM)

SYDNEY, AUSTRALIA – 24 October 2023 – Immutep Limited (ASX:IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) advises that the results of its Annual General Meeting (...read more

Immutep reports promising data from INSIGHT-003 trial (ASX:IMM)

Promising efficacy and tolerability reported from efti plus anti-PD-1 therapy and doublet chemotherapy as first line therapy in metastatic non-squamous non-small cell lung cancer con...read more

Immutep AGM 2023 - Chairman's Address (ASX:IMM)

Dear Fellow Shareholders, It’s my pleasure to welcome all our shareholders to Immutep’s Annual General Meeting 2023, a year that has seen Immutep report very encouraging clinical data...read more

Immutep AGM 2023 - CEO's Presentation (ASX:IMM)

To view the presentation, download the attached PDF.

Viewing: 121 - 135 of 200 Previous | Next